A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine [mesalazine] Pellet Formulation.

Trial Profile

A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine [mesalazine] Pellet Formulation.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 29 Dec 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top